Hyperrab

— THERAPEUTIC DISORDERS TREATED —
  • Vaccines

Hyperrab Generic Name & Formulations

General Description

Rabies immune globulin (human) 300 IU/mL; soln for IM inj; preservative-free; latex-free.

Pharmacological Class

Immune globulin.

How Supplied

Single-dose vial (1mL, 3mL, 5mL)—1

Generic Availability

NO

Hyperrab Indications

Indications

Postexposure prophylaxis of rabies (along with rabies vaccine).

Hyperrab Dosage and Administration

Adult

See full labeling. Give by IM inj preferably at the time of 1st vaccine dose; may be given through 7th day after 1st vaccine dose is given. Not previously vaccinated: 20 IU/kg (0.0665mL/kg) once. If feasible, up to full dose should be infiltrated in area around wound and the rest (if any) into deltoid muscle of upper arm or lateral thigh muscle.

Children

Not established.

Hyperrab Contraindications

Not Applicable

Hyperrab Boxed Warnings

Not Applicable

Hyperrab Warnings/Precautions

Warnings/Precautions

Previously immunized with rabies vaccine with a confirmed adequate rabies antibody titer: not recommended. Contains human plasma; monitor for possible infection transmission. IgA-deficiency. Prior history of allergic reactions to human immunoglobulins. Have epinephrine inj available. Pregnancy. Nursing mothers.

Hyperrab Pharmacokinetics

See Literature

Hyperrab Interactions

Interactions

Do not administer repeated doses after administration of rabies vaccine; may suppress immune response to the vaccine. Avoid live vaccines for 4 months (eg, measles, mumps, polio, rubella).

Hyperrab Adverse Reactions

Adverse Reactions

Inj site pain or nodule, headache, abdominal pain, diarrhea, flatulence, nasal congestion, oropharyngeal pain; hypersensitivity reactions.

Hyperrab Clinical Trials

See Literature

Hyperrab Note

Not Applicable

Hyperrab Patient Counseling

See Literature